Avenue Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights Aug 14, 2019
Mustang Bio Announces $9.28 Million Grant to Fund Phase 1 Trial of CAR T Therapy MB-103 in HER2-Positive Breast Cancer with Brain Metastases Aug 13, 2019
Mustang Bio Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights Aug 09, 2019
Fortress Biotech Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights Aug 09, 2019
Checkpoint Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights Aug 08, 2019
Avenue Therapeutics Announces Appointment of Ms. E. Garrett Ingram to Board of Directors Aug 01, 2019
Mustang Bio Receives Orphan Drug Designation for MB-102 (CD123 CAR T) for the Treatment of Acute Myeloid Leukemia Jul 24, 2019
